

表2 効用値一覧（続き）

効用値	健康状態	文献
0.39	Baseline	Dooms 2006 Eur Respir J
0.39	Disease progression in patients with diffuse large B-cell lymphoma	Best 2005 Value Health
0.4	Nursing home	Karnon 2006 Pharmacoeconomics
0.4	Gastric cancer stage IV	Dan 2006 Clin Gastroenterol Hepatol
0.4	Utility in month of death	Ramsey 2005 Urology
0.4	Distant metastasis regardless of initial treatment strategy	Suh 2005 Int J Radiat Oncol Biol Phys
0.4	Skeletal related events-free month when receiving IV pamidronate or zoledronic acid	De Cock 2005 Support Care Cancer
0.4	Metastatic bone disease	De Cock 2005 Support Care Cancer
0.4	Utility during terminal state- 1 months before death due to prostate cancer	Penson 2005 J Urol
0.4	Skeletal-related event-free month when receiving IV pamidronate or IV zoledronic acid	De Cock 2005 Clin Ther
0.4	Patients with metastatic bone disease	De Cock 2005 Clin Ther
0.41	Glioma patient after surgery and radiation, age- 45	Martikainen 2005 Pharmacoeconomics
0.42	Chemotherapy	Konski 2006 Cancer
0.42	Skeletal related events-free month when receiving oral ibandronate	De Cock 2005 Support Care Cancer
0.42	Last year of life while receiving chemotherapy and other supportive therapy for prostate cancer	Konski 2005 Int J Radiat Oncol Biol Phys
0.42	Skeletal-related event-free month when receiving oral ibandronate	De Cock 2005 Clin Ther

表2 効用値一覧（続き）

効用値	健康状態	文献
0.43	Chemotherapy alternative, Temozolomide for glioma	Martikainen 2005 Pharmacoeconomics
0.448	Ablation, hypothyroid	Mernagh 2006 Eur J Endocrinol
0.45	Utility 2 months before death	Ramsey 2005 Urology
0.45	Utility during terminal state- 2 months before death due to prostate cancer	Penson 2005 J Urol
0.45	Local and distant recurrence of rectal cancer after total mesorectal excision (TME)	van den Brink 2004 J Clin Oncol
0.45	Advanced Breast Cancer- progression during first line chemotherapy	Marchetti 2004 Clin Ther
0.46	Utility for breast cancer patient with bone metastases receiving PA with an SRE	Botteman 2006 Ann Oncol
0.462	Metastasis	Gil 2006 Clin Transl Oncol
0.48	Survival after disease progression, breast cancer	Verma 2005 Cancer
0.48	Local and distant recurrence of rectal cancer after preoperative radiotherapy (PRT) and total mesorectal excision (TME)	van den Brink 2004 J Clin Oncol
0.48	Detected invasive cervical cancer, stage IV	Goldie 2004 J Natl Cancer Inst
0.49	Progressive stage after recurrence of breast cancer	Hornberger 2005 Am J Manag Care
0.49	Disease progression in breast cancer	Elkin 2004 J Clin Oncol
0.5	Gastric cancer stage III	Dan 2006 Clin Gastroenterol Hepatol
0.5	Thyroidectomy	Mernagh 2006 Eur J Endocrinol
0.5	Life after relapse of breast cancer	Lønning 2006 Ann Oncol

表2 効用値一覧（続き）

効用値	健康状態	文献
0.5	Utility 3 months before death	Ramsey 2005 Urology
0.5	Lung cancer patients treated with CHART or conventional treatment alive with disease	Lievens 2005 Radiother Oncol
0.5	Breast cancer recurrence- chemotherapy treatment, 6 months only	Hornberger 2005 Am J Manag Care
0.5	Utility during terminal state- 3 months before death due to prostate cancer	Penson 2005 J Urol
0.5	cancer	Rubenstein 2005 Aliment Pharmacol Ther
0.5	Post-diagnosis adjuvant chemotherapy for breast cancer	Oestreicher 2005 Genet Med
0.5	Decompensated cirrhosis due to HCV	Patel 2005 Clin Gastroenterol Hepatol
0.5	Patient with bone metastasis from prostate cancer-treatment state	Konski 2004 Int J Radiat Oncol Biol Phys
0.5	Presence of HCC (chronic hepatitis C), all child's classes	Lin 2004 Aliment Pharmacol Ther
0.5	Radio-induced thyroid cancer	Vidal-Trecan 2004 Thyroid
0.51	Metastatic cancer	Moeremans 2006 Int J Gynecol Cancer
0.51	Locoregional relapse	Moeremans 2006 Int J Gynecol Cancer
0.513	Distant disease	Stout 2006 J Natl Cancer Inst
0.52	Stage III cutaneous melanoma patients, during interferon treatment	Crott 2004 Value Health
0.524	Blast phase- all treatments for chronic myeloid leukaemia	Dalziel 2005 Pharmacoeconomics
0.548	Pre-ablation, hypothyroid	Mernagh 2006 Eur J Endocrinol

表2 効用値一覧（続き）

効用値	健康状態	文献
0.55	Utility 4 months before death	Ramsey 2005 Urology
0.55	Patients with a diagnosis of colorectal cancer during primary therapy	Uyl-de Groot 2005 Vaccine
0.55	Lung cancer patients during treatment with CHART	Lievens 2005 Radiother Oncol
0.55	Utility during terminal state- 4 months before death due to prostate cancer	Penson 2005 J Urol
0.55	Glioma patient who is having their first surgery, age-45	Martikainen 2005 Pharmacoeconomics
0.56	Utility for breast cancer patient with bone metastases not receiving PA without an SRE	Botteman 2006 Ann Oncol
0.56	Positive touch imprint cytology results w/ immediate lymph node dissection with complications	Jeruss 2006 Cancer
0.56	Detected invasive cervical cancer, stage III	Goldie 2004 J Natl Cancer Inst
0.56	Detected invasive cervical cancer, stage II	Goldie 2004 J Natl Cancer Inst
0.58	Distant metastases	Karnon 2006 Pharmacoeconomics
0.58	No touch imprint cytology done w/ positive standard post-operative sentinel lymph node assessment results w/ delayed lymph node dissection with complications	Jeruss 2006 Cancer
0.59	Metastatic cancer	Plevritis 2006 JAMA
0.595	Accelerated-phase or blast crises chronic myeloid leukemia or blast crises	Reed 2004 Cancer
0.6	Chemotherapy	Konski 2006 Int J Radiat Oncol Biol Phys
0.6	Utility 5 months before death	Ramsey 2005 Urology
0.6	Alive with breast cancer + radiotherapy IM-MS	Lievens 2005 Int J Radiat Oncol Biol Phys

表2 効用値一覧（続き）

効用値	健康状態	文献
0.6	Permanent disability following intracranial bleed	Aujesky 2005 Thromb Haemost
0.6	Utility during terminal state- 5 months before death due to prostate cancer	Penson 2005 J Urol
0.6	Chemoradiotherapy for non-small cell lung carcinoma	Hayashi 2005 Ann Nucl Med
0.6	No complete responders or progression of diffuse large B-cell lymphoma (either CHOP or R-CHOP)	Groot 2005 Eur J Haematol
0.6	Initial treatment with CHOP-R for diffuse large B-cell lymphoma	Groot 2005 Eur J Haematol
0.6	Initial treatment with CHOP for diffuse large B-cell lymphoma	Groot 2005 Eur J Haematol
0.6	Patient with bone metastasis from prostate cancer-during chemotherapy	Konski 2004 Int J Radiat Oncol Biol Phys
0.6	Patient with bone metastasis from prostate cancer undergoing radiotherapy	Konski 2004 Int J Radiat Oncol Biol Phys
0.605	Radiation therapy plus total androgen suppression for prostate cancer (Quality of Well Being)	Konski 2005 Int J Radiat Oncol Biol Phys
0.614	Ablation, rhTSH	Mernagh 2006 Eur J Endocrinol
0.615	Within 30 days before or after skeletal related events (SRE) in patients with SRE	Reed 2004 J Urol
0.62	Metastatic disease	Limwattananon 2006 J Med Assoc Thai
0.62	Negative touch imprint cytology results w/ positive standard post-operative sentinel lymph node assessment results w/ delayed lymph node dissection with complications	Jeruss 2006 Cancer
0.62	10*3 arm	van den Hout 2006 J Natl Cancer Inst
0.62	After treatment for invasive cervical cancer, stage IV	Goldie 2004 J Natl Cancer Inst
0.624	Secondary cancer, salivary gland	Mernagh 2006 Eur J Endocrinol

表2 効用値一覧（続き）

効用値	健康状態	文献
0.624	Secondary cancer, bone/soft tissue	Mernagh 2006 Eur J Endocrinol
0.624	Secondary cancer (colorectal, bone/soft tissue/salivary)	Mernagh 2006 Eur J Endocrinol
0.628	Within 60 days before or after skeletal related events (SRE) in patients with SRE	Reed 2004 J Urol
0.63	Receiving adjuvant treatment with significant serious adverse events during treatment duration	Eggington 2006 Br J Cancer
0.63	Alive with breast cancer	Lievens 2005 Int J Radiat Oncol Biol Phys
0.637	0-4 weeks post-ablation, hypothyroid	Mernagh 2006 Eur J Endocrinol
0.64	Utility for breast cancer patient with bone metastases receiving PA without an SRE	Botteman 2006 Ann Oncol
0.64	Distant recurrence of rectal cancer after total mesorectal excision (TME)	van den Brink 2004 J Clin Oncol
0.642	Regional cancer	Stout 2006 J Natl Cancer Inst
0.644	Within 90 days before or after skeletal related events (SRE) in patients with SRE	Reed 2004 J Urol
0.644	All patients with multiple myeloma	van Agthoven 2004 Eur J Cancer
0.647	Hormone therapy for prostate cancer (Quality of Well Being)	Konski 2005 Int J Radiat Oncol Biol Phys
0.65	Localized disease	Limwattananon 2006 J Med Assoc Thai
0.65	Gastric cancer Stage I or II	Dan 2006 Clin Gastroenterol Hepatol
0.65	Distant metastasis	Delea 2006 Am J Manag Care
0.65	Utility 6 months before death	Ramsey 2005 Urology

表2 効用値一覧（続き）

効用値	健康状態	文献
0.65	Lung cancer patients during conventional treatment	Lievens 2005 Radiother Oncol
0.65	Utility during terminal state- 6 months before death due to prostate cancer	Penson 2005 J Urol
0.65	Detected invasive cervical cancer, stage I	Goldie 2004 J Natl Cancer Inst
0.65	Child's class B/C (decompensated cirrhosis)	Lin 2004 Aliment Pharmacol Ther
0.652	THT withdrawal - First assessment	Blamey 2005 ANZ J Surg
0.656	Radiation therapy for prostate cancer (Quality of Well Being)	Konski 2005 Int J Radiat Oncol Biol Phys
0.66	No touch imprint cytology test done w/ positive standard post-operative sentinel lymph node assessment results w/ delayed lymph node dissection and no complications	Jeruss 2006 Cancer
0.666	Secondary assessment: THT withdrawals	Blamey 2005 ANZ J Surg
0.67	Disease free hip fracture (1st year)	Delea 2006 Am J Manag Care
0.67	Local recurrence of rectal cancer after total mesorectal excision (TME)	van den Brink 2004 J Clin Oncol
0.67	Local recurrence of rectal cancer after preoperative radiotherapy (PRT) and total mesorectal excision (TME)	van den Brink 2004 J Clin Oncol
0.67	Advanced Breast Cancer- stable or responding to first line chemotherapy	Marchetti 2004 Clin Ther
0.689	Within 30 days before or after skeletal related events (SRE) in patients without SRE	Reed 2004 J Urol
0.69	Terminal phase lung cancer (3-months prior to death from lung cancer)	Manser 2005 Lung Cancer
0.69	Metastatic non-small cell lung cancer (until death)	Manser 2005 Lung Cancer
0.692	Within 60 days before or after skeletal related events (SRE) in patients without SRE	Reed 2004 J Urol

表2 効用値一覧（続き）

効用値	健康状態	文献
0.694	Within 60 days before or after skeletal related events (SRE) in patients without SRE	Reed 2004 J Urol
0.7	Lymphoma	Swigonski 2006 Pediatrics
0.7	High dose chemotherapy after failure of conventional salvage	Guadagnolo 2006 J Clin Oncol
0.7	Adjuvant treatment with no significant serious adverse events	Eggington 2006 Br J Cancer
0.7	Stable stage after recurrence of breast cancer	Hornberger 2005 Am J Manag Care
0.7	Radiotherapy for non-small cell lung carcinoma	Hayashi 2005 Ann Nucl Med
0.7	Hip Fracture as breast cancer treatment-related event	Hillner 2004 Cancer
0.7	Systemic recurrence of breast cancer	Hillner 2004 Cancer
0.7	Distant recurrence of rectal cancer after preoperative radiotherapy (PRT) and total mesorectal excision (TME)	van den Brink 2004 J Clin Oncol
0.7	Time from preoperative radiotherapy (PRT) to surgery for rectal cancer	van den Brink 2004 J Clin Oncol
0.7	Stable disease while on breast cancer therapy	Elkin 2004 J Clin Oncol
0.7	Stroke, moderate disability	Cykert 2004 Obstet Gynecol
0.7	Stroke, mild disability	Cykert 2004 Obstet Gynecol
0.71	Ovarian cancer	Plevritis 2006 JAMA
0.71	Negative touch imprint cytology results w/ positive standard post-operative sentinel lymph node assessment results w/ delayed lymph node dissection and no complications	Jeruss 2006 Cancer
0.71	Positive touch imprint cytology results w/ immediate lymph node dissection and no complications	Jeruss 2006 Cancer

表2 効用値一覧（続き）

効用値	健康状態	文献
0.71	IFN +LDAC therapy for chronic-phase chronic myeloid leukemia	Reed 2004 Cancer
0.7104	Cytogenetic response- Interferon alpha treatment for chronic myeloid leukaemia	Dalziel 2005 Pharmacoeconomics
0.7104	Chronic phase- Interferon alpha treatment for chronic myeloid leukaemia	Dalziel 2005 Pharmacoeconomics
0.712	0-4 weeks post-ablation, rhTSH	Mernagh 2006 Eur J Endocrinol
0.714	Pre-ablation, rhTSH	Mernagh 2006 Eur J Endocrinol
0.718	Local recurrence	Gil 2006 Clin Transl Oncol
0.72	Chemotherapy	Limwattananon 2006 J Med Assoc Thai
0.72	STRETCH patients-improvers	Gordon 2005 Breast Cancer Res Treat
0.72	Breast cancer survivors with no further intervention	Gordon 2005 Breast Cancer Res Treat
0.724	Distant recurrence in breast cancer patients	Rocchi 2006 Support Care Cancer
0.729	Hormone therapy	Konski 2006 Int J Radiat Oncol Biol Phys
0.729	Accelerated phase- all treatments for chronic myeloid leukaemia	Dalziel 2005 Pharmacoeconomics
0.73	STRETCH patients-non improvers	Gordon 2005 Breast Cancer Res Treat
0.73	Disease progression-free survival, breast cancer	Verma 2005 Cancer
0.73	Time from surgery to discharge for patients with distant rectal metastases at surgery in the PRT + TME group.	van den Brink 2004 J Clin Oncol
0.739	Hormone therapy for prostate cancer (Health Utilities Index)	Konski 2005 Int J Radiat Oncol Biol Phys

表2 効用値一覧 (続き)

効用値	健康状態	文献
0.74	Radioactive iodine treatment (high or low dose) - failure to achieve euthyroidism	Vidal-Trecan 2004 Thyroid
0.741	Disease free with complications	Gil 2006 Clin Transl Oncol
0.749	Patient on radiotherapy (RT) and Androgen deprivation (AD)	Konski 2006 Cancer
0.749	Radiation therapy plus total androgen suppression for prostate cancer (Patient-Oriented Prostate Utility Scale- Rating Scale)	Konski 2005 Int J Radiat Oncol Biol Phys
0.75	No disease	Limwattananon 2006 J Med Assoc Thai
0.75	Treatment for breast cancer + radiotherapy IM-MS	Lievens 2005 Int J Radiat Oncol Biol Phys
0.759	4-8 weeks post-ablation, hypothyroid	Mernagh 2006 Eur J Endocrinol
0.77	Breast cancer in situ	Stout 2006 J Natl Cancer Inst
0.77	Locoregional recurrence (1st year)	Delea 2006 Am J Manag Care
0.77	Contralateral tumor (1st year)	Delea 2006 Am J Manag Care
0.77	Non-intervention patients-improvers	Gordon 2005 Breast Cancer Res Treat
0.77	Non-intervention patients-improvers	Gordon 2005 Breast Cancer Res Treat
0.77	Cancer	Aujesky 2005 Thromb Haemost
0.775	Contralateral breast cancer	Rocchi 2006 Support Care Cancer
0.78	Randomization to preoperative radiotherapy (PRT) or surgery for rectal cancer	van den Brink 2004 J Clin Oncol
0.78	Child's class A (compensated cirrhosis)	Lin 2004 Aliment Pharmacol Ther

表2 効用値一覧（続き）

効用値	健康状態	文献
0.785	Usual therapy + paclitaxel	Limwattananon 2006 J Med Assoc Thai
0.79	No evidence of disease + radiotherapy IM-MS	Lievens 2005 Int J Radiat Oncol Biol Phys
0.793	Androgen deprivation (AD)	Konski 2006 Cancer
0.793	Hormone therapy for prostate cancer (Patient-Oriented Prostate Utility Scale- Rating Scale)	Konski 2005 Int J Radiat Oncol Biol Phys
0.795	On rhTRH - First assessment	Blamey 2005 ANZ J Surg
0.796	4-8 weeks post-ablation, rhTSH	Mernagh 2006 Eur J Endocrinol
0.797	Secondary assessment (all patients): On rhTSH	Blamey 2005 ANZ J Surg
0.8	Hip Fracture	Karnon 2006 Pharmacoeconomics
0.8	Persistent disease after high dose chemotherapy	Guadagnolo 2006 J Clin Oncol
0.8	High dose chemotherapy	Guadagnolo 2006 J Clin Oncol
0.8	Treatment for breast cancer	Lievens 2005 Int J Radiat Oncol Biol Phys
0.8	Chemotherapy with major toxicity	Naeim 2005 Breast Cancer Res Treat
0.8	DAART patients (improvers)	Gordon 2005 Breast Cancer Res Treat
0.8	STRETCH treatment participants	Gordon 2005 Breast Cancer Res Treat
0.8	Growth hormone deficiency	Lundkvist 2005 Acta Oncol
0.8	Increased risk of other cardiovascular disease	Lundkvist 2005 Acta Oncol

表 2 効用値一覧（続き）

効用値	健康状態	文献
0.8	Regional non-small cell lung cancer (disease free after treatment, until relapse or death from other causes)	Manser 2005 Lung Cancer
0.8	Post-operative health state after surgery for lung cancer (at 6-month time point)	Manser 2005 Lung Cancer
0.8	Other cardiovascular diseases	Lundkvist 2005 Radiother Oncol
0.8	Post-diagnosis: no adjuvant chemotherapy for breast cancer	Oestreicher 2005 Genet Med
0.8	Chemotherapy with major toxicity for node (-) early breast cancer	Naeim 2005 Crit Rev Oncol Hematol
0.8	Post living donor liver transplant for hepatocellular carcinoma	Patel 2005 Clin Gastroenterol Hepatol
0.8	Post cadaveric liver transplant for hepatocellular carcinoma	Patel 2005 Clin Gastroenterol Hepatol
0.8	Post resection for hepatocellular carcinoma	Patel 2005 Clin Gastroenterol Hepatol
0.8	Compensated cirrhosis due to HCV	Patel 2005 Clin Gastroenterol Hepatol
0.8	Time from surgery to discharge for patients with distant rectal metastases at surgery in the TME group.	van den Brink 2004 J Clin Oncol
0.8	Advanced Breast Cancer- progression during second line hormone therapy	Marchetti 2004 Clin Ther
0.8	Advanced Breast Cancer- stable, responding or progression during first line hormone therapy	Marchetti 2004 Clin Ther
0.801	Pre-treatment - First assessment	Blamey 2005 ANZ J Surg
0.802	Secondary assessment (all patients): Pre-treatment	Blamey 2005 ANZ J Surg
0.81	Remission (follow up)	Moeremans 2006 Int J Gynecol Cancer
0.81	Lumpectomy with invasive local recurrence salvaged with conservative surgery and RT	Suh 2005 Int J Radiat Oncol Biol Phys

表2 効用値一覧（続き）

効用値	健康状態	文献
0.81	Lumpectomy and RT with invasive local recurrence salvaged with mastectomy	Suh 2005 Int J Radiat Oncol Biol Phys
0.81	Radiation therapy for prostate cancer (Patient-Oriented Prostate Utility Scale- Rating Scale)	Konski 2005 Int J Radiat Oncol Biol Phys
0.81	Progression free diffuse large B-cell lymphoma (either CHOP or R-CHOP)	Groot 2005 Eur J Haematol
0.81	Pulmonary embolism	Cykert 2004 Obstet Gynecol
0.812	Conformal RT	Konski 2006 Int J Radiat Oncol Biol Phys
0.816	Local breast cancer recurrence	Rocchi 2006 Support Care Cancer
0.816	Radiation therapy plus total androgen suppression for prostate cancer (Patient-Oriented Prostate Utility Scale- Standard Gamble)	Konski 2005 Int J Radiat Oncol Biol Phys
0.8175	Doxorubicin and cyclophosphamide therapy	Limwattananon 2006 J Med Assoc Thai
0.818	Radiation therapy plus total androgen suppression for prostate cancer (Health Utilities Index)	Konski 2005 Int J Radiat Oncol Biol Phys
0.82	Locoregional recurrence- Year1	Karnon 2006 Pharmacoeconomics
0.82	Contralateral tumor- Year 1	Karnon 2006 Pharmacoeconomics
0.82	Disease free without complications	Gil 2006 Clin Transl Oncol
0.82	No evidence of disease	Lievens 2005 Int J Radiat Oncol Biol Phys
0.82	Hearing loss	Lundkvist 2005 Acta Oncol
0.825	Radiation therapy for prostate cancer (Health Utilities Index)	Konski 2005 Int J Radiat Oncol Biol Phys
0.83	Breast cancer	Plevritis 2006 JAMA

表 2 効用値一覧（続き）

効用値	健康状態	文献
0.83	Currative primary therapy	Uyl-de Groot 2005 Vaccine
0.83	Salvage or transplant therapy	Hornberger 2005 Cancer
0.83	Event-free life on CHOP or R-CHOP	Hornberger 2005 Cancer
0.83	Disease free survival in patients with diffuse large B-cell lymphoma	Best 2005 Value Health
0.83	Curable endometrial cancer	Cykert 2004 Obstet Gynecol
0.83	Curable breast cancer	Cykert 2004 Obstet Gynecol
0.84	No touch imprint cytology done w/ negative standard post-operative sentinel lymph node assessment results w/ no lymph node dissection	Jeruss 2006 Cancer
0.84	DAART treatment participants	Gordon 2005 Breast Cancer Res Treat
0.84	Lumpectomy with invasive local recurrence salvaged with mastectomy	Suh 2005 Int J Radiat Oncol Biol Phys
0.84	Patients after recurrence and responding to chemotherapy for advanced breast cancer	Hornberger 2005 Am J Manag Care
0.84	Responding to breast cancer therapy	Elkin 2004 J Clin Oncol
0.84	Patient with relapse of colorectal cancer	Borie 2004 World J Surg
0.841	Mammogram with positive results	Stout 2006 J Natl Cancer Inst
0.85	Conventional dose salvage	Guadagnolo 2006 J Clin Oncol
0.85	DAART patients (non-improvers)	Gordon 2005 Breast Cancer Res Treat
0.852	Mammogram with negative results	Stout 2006 J Natl Cancer Inst

表2 効用値一覧 (続き)

効用値	健康状態	文献
0.8539	Chronic phase and cytogenetic responses-imatinib treatment for chronic myeloid leukaemia	Dalziel 2005 Pharmacoeconomics
0.854	Imatinib therapy for chronic-phase chronic myeloid leukemia	Reed 2004 Cancer
0.855	Metastases with bicalutamide (casodex) treatment	Moeremans 2004 Value Health
0.856	Healthy	Stout 2006 J Natl Cancer Inst
0.86	Disease-free first year	Moeremans 2006 Int J Gynecol Cancer
0.86	Hormone therapy for prostate cancer (Patient-Oriented Prostate Utility Scale- Standard Gamble)	Konski 2005 Int J Radiat Oncol Biol Phys
0.86	Greater than 9 months beyond surgery for patients with microscopically negative rectal metastases at surgery and have no stoma	van den Brink 2004 J Clin Oncol
0.86	Deep venous thrombosis- no postphlebotic syndrome	Cykert 2004 Obstet Gynecol
0.87	Lung cancer patients treated with CHART or conventional treatment and no evidence of disease	Lievens 2005 Radiother Oncol
0.877	Radiation therapy for prostate cancer (Patient-Oriented Prostate Utility Scale- Standard Gamble)	Konski 2005 Int J Radiat Oncol Biol Phys
0.88	Lumpectomy and RT with noninvasive local recurrence salvaged with mastectomy	Suh 2005 Int J Radiat Oncol Biol Phys
0.88	Lung cancer 'overdiagnosed' by screening (until death from other causes)	Manser 2005 Lung Cancer
0.88	Localized non-small cell lung cancer (disease after treatment, until relapse or death from other causes)	Manser 2005 Lung Cancer
0.88	Post-operative health state after surgery for false positive	Manser 2005 Lung Cancer
0.88	Post-MI, complication due to chemoprevention of colorectal carcinoma	Hur 2004 Cancer
0.89	Negative touch imprint cytology results w/ negative standard post-operative sentinel lymph node assessment results w/ no lymph node dissection	Jeruss 2006 Cancer

表2 効用値一覧（続き）

効用値	健康状態	文献
0.89	Lumpectomy with noninvasive local recurrence salvaged with mastectomy	Suh 2005 Int J Radiat Oncol Biol Phys
0.89	Greater than 9 months beyond surgery for patients with microscopically positive rectal metastases or incomplete local resection at surgery and have no stoma	van den Brink 2004 J Clin Oncol
0.9	Relapse to Hodgkin's disease	Guadagnolo 2006 J Clin Oncol
0.9	Chemotherapy with minor toxicity	Naeim 2005 Breast Cancer Res Treat
0.9	Hypothyroidism	Lundkvist 2005 Acta Oncol
0.9	Increased risk of ischemic heart disease	Lundkvist 2005 Acta Oncol
0.9	Lumpectomy with noninvasive local recurrence salvaged with conservative surgery and RT	Suh 2005 Int J Radiat Oncol Biol Phys
0.9	Lumpectomy without recurrence	Suh 2005 Int J Radiat Oncol Biol Phys
0.9	Lumpectomy and RT without recurrence	Suh 2005 Int J Radiat Oncol Biol Phys
0.9	Ischemic heart disease	Lundkvist 2005 Radiother Oncol
0.9	No evidence of breast cancer	Oestreicher 2005 Genet Med
0.9	Chemotherapy with minor toxicity for node (-) early breast cancer	Naeim 2005 Crit Rev Oncol Hematol
0.9	After treatment for invasive cervical cancer, stage III	Goldie 2004 J Natl Cancer Inst
0.9	After treatment for invasive cervical cancer, stage II	Goldie 2004 J Natl Cancer Inst
0.9	Patients without colorectal cancer recurrence after 5 years	Borie 2004 World J Surg
0.9	Deep venous thrombosis- postphlebotic syndrome	Cykert 2004 Obstet Gynecol

表2 効用値一覧（続き）

効用値	健康状態	文献
0.9	PSA progression while not on bicalutamide (casodex) treatment	Moeremans 2004 Value Health
0.9	PSA progression while on bicalutamide (casodex) treatment	Moeremans 2004 Value Health
0.9	Chronic myeloid leukemia - chronic phase	Warren 2004 Clin Ther
0.9	Coincidental or radio-induced thyroid cancer - cancer becomes clinically evident	Vidal-Trecan 2004 Thyroid
0.905	Intensity-modulated radiation therapy (IMRT)	Konski 2006 Int J Radiat Oncol Biol Phys
0.91	Vertebral fracture	Karnon 2006 Pharmacoeconomics
0.91	Ulcer, complication due to chemoprevention of colorectal carcinoma	Hur 2004 Cancer
0.91	Chronic myeloid leukemia - blast crisis - tx with chemotherapy	Warren 2004 Clin Ther
0.92	Disease-free consecutive years	Moeremans 2006 Int J Gynecol Cancer
0.92	Disease-free following adjuvant treatment	Eggington 2006 Br J Cancer
0.93	Disease free hip fracture (>2 year)	Delea 2006 Am J Manag Care
0.93	Severe urogenital (UG) adverse event	Lundkvist 2005 Acta Oncol
0.93	Mild urogenital (UG) adverse event	Lundkvist 2005 Acta Oncol
0.93	Severe GI adverse event	Lundkvist 2005 Acta Oncol
0.93	Mild GI adverse event	Lundkvist 2005 Acta Oncol
0.932	Early prostate cancer in treatment with bicalutamide (casodex)	Moeremans 2004 Value Health

表2 効用値一覧（続き）

効用値	健康状態	文献
0.9337	Early prostate cancer in treatment without bicalutamide (casodex)	Moeremans 2004 Value Health
0.945	Men with prostate cancer, age- 55	Zeliadt 2005 Am J Med
0.95	Postoperative state for non-small cell lung carcinoma	Hayashi 2005 Ann Nucl Med
0.95	Surgery followed by hypoparathyroidism	Vidal-Trecan 2004 Thyroid
0.95	Hyperthyroidism treatment	Vidal-Trecan 2004 Thyroid
0.97	Locoregional recurrence- Year 2+	Karnon 2006 Pharmacoeconomics
0.97	Contralateral tumor- Year 2+	Karnon 2006 Pharmacoeconomics
0.97	Disease free	Karnon 2006 Pharmacoeconomics
0.97	Locoregional recurrence (>2 year)	Delea 2006 Am J Manag Care
0.97	Contralateral tumor (>2 year)	Delea 2006 Am J Manag Care
0.97	Disease free, no hip fracture	Delea 2006 Am J Manag Care
0.97	Post-oesophagectomy	Rubenstein 2005 Aliment Pharmacol Ther
0.97	After treatment for invasive cervical cancer, stage I	Goldie 2004 J Natl Cancer Inst
0.97	Noncerebral bleed, complication due to chemoprevention of colorectal carcinoma	Hur 2004 Cancer
0.974	No breast cancer	Rocchi 2006 Support Care Cancer
0.98	Proximal humerus fracture	Karnon 2006 Pharmacoeconomics

表2 効用値一覧（続き）

効用値	健康状態	文献
0.98	Wrist fracture	Karnon 2006 Pharmacoeconomics
0.98	False-positive CT scan	Guadagnolo 2006 J Clin Oncol
0.98	Osteoporosis	Lundkvist 2005 Acta Oncol
0.98	False positive (anxiety associated with expectant management; 6-month until follow-up)	Manser 2005 Lung Cancer
0.98	Breast cancer patients after chemotherapy and no distance recurrence	Hornberger 2005 Am J Manag Care
0.98	Men with benign prostatic, age- 55	Zeliadt 2005 Am J Med
0.98	Transient dysphonia following surgery	Vidal-Trecan 2004 Thyroid
0.99	GFD- gluten-free diet	Swigonski 2006 Pediatrics
0.99	Symptoms on follow-up	Guadagnolo 2006 J Clin Oncol
0.99	Hormone Therapy	Naeim 2005 Breast Cancer Res Treat
0.99	Anticoagulation with low molecular weight heparin	Aujesky 2005 Thromb Haemost
0.99	Anticoagulation with wafarin	Aujesky 2005 Thromb Haemost
0.99	Hormone therapy for node (-) early breast cancer	Naeim 2005 Crit Rev Oncol Hematol
0.99	Coincidental or radio-induced thyroid cancer - detected thyroid cancer during primary surgery	Vidal-Trecan 2004 Thyroid
0.99	Radioactive iodine treatment (high or low dose) or surgery, followed by hypothyroidism	Vidal-Trecan 2004 Thyroid
0.999	Radioactive iodine treatment (high or low dose)	Vidal-Trecan 2004 Thyroid
1	BRAC status	Plevritis 2006 JAMA

## (資料 10) がんの QOL 評価のための効用値の測定ツールの開発

研究分担者 池田 俊也 (国際医療福祉大学薬学部薬学科 教授)

研究協力者 清水 隆明 (国際医療福祉大学大学院)

中村 真理 (国際医療福祉大学大学院)

### 研究要旨

効用値を用いたがんの QOL 評価を目的として、時間得失法により効用値を算出するための測定ツールを開発し、がんの薬物療法によって生じる代表的な副作用ならびに緩和治療を受けている状態について、一般人 30 名を対象に効用値の測定を試みた。その結果、本測定ツールによりがん治療に関連したさまざまな病態に対する効用値を容易に測定できることが確認された。また、副作用や緩和治療に対する価値づけは個人によりさまざまであり、がん対策の評価にあたっては個人の意向や価値観の違いに配慮する必要があると考えられた。今後、効用値測定ツールを他の年齢層や患者集団においても試用して効用値測定ツールの妥当性検証を行うとともに、がん対策の効果や医療経済評価への適用可能性についてさらに検討を行っていく必要があると思われた。

### A. 研究目的

医療経済評価を実施する際の効果指標として、質調整生存年 (QALYs, Quality-Adjusted Life Years) の利用が進んでいる。とくにがんの場合には、病態の進行や治療に伴い QOL の低下が認められることも多く、生存年ではなく質調整生存年を用いることが望ましいと考えられている。さらに、患者の治療法選択に際しても、延命効果だけではなく QOL も考慮して総合的に判断を行うためには、質調整生存年の考え方が参考になるものと思われる。

質調整生存年の算出を行うための QOL ウェイトは、死亡を 0、完全な健康を 1 とする間隔尺度であり、効用値 (utility) と呼ばれる。効用値を設定するための方法として、評点尺度法、基準的賭け法、時間得失法、EuroQol 等の「選好に基づく尺度」による換算などの方法が用いられているが、我が国においてはこれらの手法を用いた効用値の測定は十分に行われてきていない。そこで今回は、時間得失法を用いて一般人や患者から効用値を収集するための Web ベースでの interactive な調査ツールを開発し、その有用性と課題について検討することとした。

### B. 研究方法

#### (1) 効用値測定ツールの開発

がんの薬物療法によって生じる代表的な副作用ならびに、緩和治療を受けている状態について、時間得失法により効用値を算出するための測定ツールを作成した。ソフトは SPSS 社の Dimensions mrInterview 5.0 を使い、インターネットのウェブサイトにて回答が行えるようにした。

副作用項目については、わが国において最近実施された抗がん剤 S-1 治療 (以下、単剤治療と略) と S-1+cisplatin 治療 (以下、併用治療と略) の延命効果並びに副作用発現状況を比較した研究 (SPIRITS trial, Koizumi et al, 2008) において報告された副作用を参考に、患者の QOL に影響が大きいと考えられる口内炎、貧血、発熱、食欲不振、悪心、疲労、嘔吐、下痢、発疹、流涙の 10 項目について、有害事象共通用語規準における Grade3~4 の重度の場合とした (表 1)。これに、「緩和治療」を追加し、11 項目について調査を行うこととした。